Trospium Dosage
This dosage information may not include all the information needed to use Trospium safely and effectively. See additional information for Trospium.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Geriatric Dose for:
Additional dosage information:
Usual Adult Dose for Urinary Incontinence
Immediate-release tablets:
20 mg orally twice daily
Extended-release capsules:
60 mg orally once daily in the morning
Usual Adult Dose for Urinary Frequency
Immediate-release tablets:
20 mg orally twice daily
Extended-release capsules:
60 mg orally once daily in the morning
Usual Geriatric Dose for Urinary Incontinence
Immediate-release tablets:
Greater than or equal to 75 years: 20 mg orally once daily.
Usual Geriatric Dose for Urinary Frequency
Immediate-release tablets:
Greater than or equal to 75 years: 20 mg orally once daily.
Renal Dose Adjustments
Immediate-release tablets:
CrCl 30 mL/min: 20 mg orally once daily at bedtime
Extended-release capsules:
CrCl 30 mL/min: Not recommended
CrCl 30 to 80 mL/min: Data not available
Liver Dose Adjustments
Caution should be exercised when using trospium chloride in patients with moderate and severe hepatic dysfunction.
Precautions
Trospium chloride is contraindicated in patients with gastric retention, uncontrolled narrow-angle glaucoma, or urinary retention, and in patients who are at risk for these conditions.
Caution should be exercised when using trospium chloride in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.
Patients treated for narrow-angle glaucoma in whom treatment with trospium chloride is considered to provide benefit should be closely monitored.
Trospium chloride, similarly to other anticholinergic drugs, may decrease gastrointestinal motility and caution should be used when treating patients with conditions such as intestinal atony, ulcerative colitis, and myasthenia gravis.
Trospium chloride should be used with caution in patients with moderate or severe hepatic dysfunction.
In two US placebo controlled studies, the incidence of commonly reported anticholinergic adverse events (including dry mouth, constipation, dyspepsia, UTI, urinary retention) was higher in patients 75 years of age and older as compared to younger patients. This effect may be related to an enhanced sensitivity to anticholinergic drugs in this patient population.
The safety and efficacy of trospium in pediatric patients has been determined.
Dialysis
Data not available
Other Comments
The dose should be given at least one hour before meals or given on an empty stomach.
